A Chinese study just published shows that in a U87 GBM mouse model, mice given intravenous disulfiram alone had only minor therapeutic benefits, while the mice given intravenous disulfiram plus copper (by stomach) had significantly increased therapeutic benefit, including reduced microvessel density and tumor volume (see figure 8). I've uploaded this study to the Brain Tumor Library.
There has been considerable debate whether additional copper beyond what is already in the stomach or bloodstream is required to potentiate the anti-cancer effect of disulfiram. Several mouse studies including the one above have shown that orally delivered copper in mice increases the therapeutic effects of disulfiram. The original CUSP9 protocol has dosing information on copper gluconate.
Please note that the addition of copper likely also increases the risk of unwanted side-effects such as peripheral neuropathy (see second study below).
Copper improves the anti-angiogenic activity of disulfiram through the EGFR/src/VEGF pathway in gliomas
N,N-Diethyldithiocarbamate Produces Copper Accumulation, Lipid Peroxidation, and Myelin Injury in Rat Peripheral Nerve
Both of these studies may be found in the Library.